BPC-157 Arginate
Also called PDA, Pentadeca Arginate
No single human route established in this referenceEvidence gap
Research reference
Evidence gap
BPC-157 arginate evidence gap
No source-backed schedule
No established human course
When results may show
BPC-157 Arginate
Evidence gap- When change was measured
- No measured human outcome window identified for this exact material.
- When to assess
- No established human course
- Conditions and limitations
- No exact-product primary protocol located in this review. No exact-salt primary protocol was located. Parent BPC-157 animal work does not prove oral absorption, a superior effect or a human arginate course.
- When to stop
- The measured study window is not a validated personal quit rule. Do not increase or prolong exposure because an expected result is absent; severe or persistent reactions need prompt clinical review.
No direct outcome source identified. See the compound page for evidence grading.
Research timing is descriptive, not a promise or personal instruction. A severe or persistent reaction needs prompt clinical review. This is not medical advice.
Modelled level — every day
1× is the peak after a single dose.
- Steady-state peak
- 1.02× single dose
- Time to steady state
- 20hours
- Administrations
- 7/ week
Read off the modelled curve, not an even-interval formula
About five half-lives